Transcode Deferred Long Term Liab vs Net Invested Capital Analysis

RNAZ Stock

USD 0.27 0.01 3.57%

Transcode Therapeutics financial indicator trend analysis is much more than just breaking down Transcode Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Transcode Therapeutics is a good investment. Please check the relationship between Transcode Therapeutics Deferred Long Term Liab and its Net Invested Capital accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Deferred Long Term Liab vs Net Invested Capital

Deferred Long Term Liab vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Transcode Therapeutics Deferred Long Term Liab account and Net Invested Capital. At this time, the significance of the direction appears to have no relationship.

The correlation between Transcode Therapeutics' Deferred Long Term Liab and Net Invested Capital is 0.0. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Transcode Therapeutics, assuming nothing else is changed. The correlation between historical values of Transcode Therapeutics' Deferred Long Term Liab and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Transcode Therapeutics are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Deferred Long Term Liab i.e., Transcode Therapeutics' Deferred Long Term Liab and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.0

Relationship Direction	Flat
Relationship Strength	Insignificant

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from Transcode Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Transcode Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.At this time, Transcode Therapeutics' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 0.07 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 11.7 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	42.5K	98.6K	516.7K	304.6K
Interest Income	664.0	20.4K	14.8K	7.9K

Depreciation And Amortization Interest Income

Transcode Therapeutics fundamental ratios Correlations

	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Other Stockholder Equity	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital
Total Current Liabilities		0.83	0.57	-0.83	0.87	0.65	0.08	0.67	-0.6	0.92	0.53	-0.58	0.98	0.54	0.69	0.21	-0.01	0.85	0.54	-0.42	0.55	0.11	0.76	0.48	0.39	0.43
Other Liab	0.83		0.52	-0.83	0.87	0.64	-0.24	0.67	-0.25	0.9	0.47	-0.53	0.81	0.53	0.86	0.64	0.42	0.95	0.53	-0.61	0.68	0.1	0.93	0.45	0.15	0.42
Net Tangible Assets	0.57	0.52		-0.34	0.59	0.98	0.36	0.97	-0.57	0.59	0.99	-0.99	0.52	0.98	0.33	-0.13	-0.18	0.52	0.98	-0.17	0.22	-0.38	0.25	0.98	0.56	0.96
Retained Earnings	-0.83	-0.83	-0.34		-0.96	-0.39	0.46	-0.44	0.59	-0.95	-0.24	0.28	-0.79	-0.24	-0.95	-0.39	0.02	-0.74	-0.24	0.84	-0.92	0.17	-0.71	-0.18	0.16	-0.11
Other Stockholder Equity	0.87	0.87	0.59	-0.96		0.63	-0.29	0.67	-0.67	0.99	0.5	-0.53	0.83	0.49	0.92	0.29	-0.07	0.78	0.49	-0.78	0.85	-0.26	0.69	0.45	0.03	0.38
Total Current Assets	0.65	0.64	0.98	-0.39	0.63		0.37	1.0	-0.49	0.65	0.98	-0.99	0.62	0.98	0.38	0.0	-0.03	0.63	0.98	-0.19	0.22	-0.22	0.41	0.97	0.62	0.95
Common Stock	0.08	-0.24	0.36	0.46	-0.29	0.37		0.31	-0.08	-0.2	0.45	-0.45	0.15	0.45	-0.61	-0.57	-0.2	-0.11	0.45	0.71	-0.72	0.34	-0.18	0.47	0.9	0.5
Total Assets	0.67	0.67	0.97	-0.44	0.67	1.0	0.31		-0.51	0.69	0.96	-0.98	0.64	0.97	0.43	0.03	-0.02	0.66	0.97	-0.25	0.28	-0.23	0.44	0.95	0.58	0.94
Short Long Term Debt Total	-0.6	-0.25	-0.57	0.59	-0.67	-0.49	-0.08	-0.51		-0.63	-0.51	0.47	-0.57	-0.4	-0.41	0.49	0.77	-0.18	-0.4	0.45	-0.5	0.53	-0.01	-0.43	-0.16	-0.34
Other Current Liab	0.92	0.9	0.59	-0.95	0.99	0.65	-0.2	0.69	-0.63		0.52	-0.56	0.9	0.52	0.89	0.31	0.0	0.83	0.52	-0.72	0.79	-0.13	0.76	0.47	0.14	0.41
Total Stockholder Equity	0.53	0.47	0.99	-0.24	0.5	0.98	0.45	0.96	-0.51	0.52		-1.0	0.5	0.99	0.23	-0.16	-0.15	0.49	0.99	-0.05	0.1	-0.31	0.22	1.0	0.65	0.98
Net Debt	-0.58	-0.53	-0.99	0.28	-0.53	-0.99	-0.45	-0.98	0.47	-0.56	-1.0		-0.55	-1.0	-0.26	0.09	0.07	-0.56	-1.0	0.06	-0.11	0.23	-0.31	-0.99	-0.67	-0.98
Accounts Payable	0.98	0.81	0.52	-0.79	0.83	0.62	0.15	0.64	-0.57	0.9	0.5	-0.55		0.51	0.63	0.16	0.0	0.8	0.51	-0.4	0.48	0.22	0.78	0.45	0.46	0.4
Cash	0.54	0.53	0.98	-0.24	0.49	0.98	0.45	0.97	-0.4	0.52	0.99	-1.0	0.51		0.24	-0.05	-0.02	0.56	1.0	-0.03	0.08	-0.21	0.31	0.99	0.67	0.99
Non Current Assets Total	0.69	0.86	0.33	-0.95	0.92	0.38	-0.61	0.43	-0.41	0.89	0.23	-0.26	0.63	0.24		0.57	0.16	0.75	0.24	-0.9	0.96	-0.25	0.72	0.18	-0.31	0.13
Non Currrent Assets Other	0.21	0.64	-0.13	-0.39	0.29	0.0	-0.57	0.03	0.49	0.31	-0.16	0.09	0.16	-0.05	0.57		0.87	0.64	-0.05	-0.37	0.43	0.3	0.73	-0.13	-0.33	-0.1
Other Assets	-0.01	0.42	-0.18	0.02	-0.07	-0.03	-0.2	-0.02	0.77	0.0	-0.15	0.07	0.0	-0.02	0.16	0.87		0.46	-0.02	0.04	-0.04	0.59	0.6	-0.1	-0.02	-0.02
Long Term Debt	0.85	0.95	0.52	-0.74	0.78	0.63	-0.11	0.66	-0.18	0.83	0.49	-0.56	0.8	0.56	0.75	0.64	0.46		0.56	-0.4	0.54	0.19	0.91	0.48	0.26	0.47
Cash And Short Term Investments	0.54	0.53	0.98	-0.24	0.49	0.98	0.45	0.97	-0.4	0.52	0.99	-1.0	0.51	1.0	0.24	-0.05	-0.02	0.56		-0.03	0.08	-0.21	0.31	0.99	0.67	0.99
Common Stock Total Equity	-0.42	-0.61	-0.17	0.84	-0.78	-0.19	0.71	-0.25	0.45	-0.72	-0.05	0.06	-0.4	-0.03	-0.9	-0.37	0.04	-0.4	-0.03		-0.95	0.42	-0.45	0.0	0.51	0.06
Common Stock Shares Outstanding	0.55	0.68	0.22	-0.92	0.85	0.22	-0.72	0.28	-0.5	0.79	0.1	-0.11	0.48	0.08	0.96	0.43	-0.04	0.54	0.08	-0.95		-0.43	0.51	0.04	-0.5	-0.03
Non Current Liabilities Total	0.11	0.1	-0.38	0.17	-0.26	-0.22	0.34	-0.23	0.53	-0.13	-0.31	0.23	0.22	-0.21	-0.25	0.3	0.59	0.19	-0.21	0.42	-0.43		0.45	-0.28	0.41	-0.23
Total Liab	0.76	0.93	0.25	-0.71	0.69	0.41	-0.18	0.44	-0.01	0.76	0.22	-0.31	0.78	0.31	0.72	0.73	0.6	0.91	0.31	-0.45	0.51	0.45		0.21	0.18	0.2
Net Invested Capital	0.48	0.45	0.98	-0.18	0.45	0.97	0.47	0.95	-0.43	0.47	1.0	-0.99	0.45	0.99	0.18	-0.13	-0.1	0.48	0.99	0.0	0.04	-0.28	0.21		0.66	0.99
Capital Stock	0.39	0.15	0.56	0.16	0.03	0.62	0.9	0.58	-0.16	0.14	0.65	-0.67	0.46	0.67	-0.31	-0.33	-0.02	0.26	0.67	0.51	-0.5	0.41	0.18	0.66		0.68
Net Working Capital	0.43	0.42	0.96	-0.11	0.38	0.95	0.5	0.94	-0.34	0.41	0.98	-0.98	0.4	0.99	0.13	-0.1	-0.02	0.47	0.99	0.06	-0.03	-0.23	0.2	0.99	0.68

Click cells to compare fundamentals

Transcode Therapeutics Account Relationship Matchups

Transcode Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	62.9K	404.9K	2.5M	4.3M	3.5M	2.0M
Net Tangible Assets	(1.1M)	(3.4M)	20.4M	3.2M	3.7M	4.1M
Retained Earnings	(1.1M)	(3.5M)	(10.3M)	(27.9M)	(46.4M)	(44.1M)
Other Stockholder Equity	7.7K	65.9K	30.7M	31.1M	48.1M	50.5M
Total Current Assets	204.5K	831.2K	22.7M	7.4M	4.5M	6.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Transcode Deferred Long Term Liab vs Net Invested Capital Analysis

Deferred Long Term Liab vs Net Invested Capital

Deferred Long Term Liab vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Net Invested Capital

Transcode Therapeutics fundamental ratios Correlations

Transcode Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Transcode Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Transcode Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	+ 1.0	Total Current Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Net Tangible Assets
Other Current Liab	+ 0.99	Other Stockholder Equity
Cash	+ 0.99	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Net Invested Capital	- 0.99	Net Debt
Net Debt	- 0.99	Total Current Assets
Net Debt	- 0.99	Net Tangible Assets